Upon request, we establish the required characteristics of the iPSC with the client. Ncardia then idenitifies applicable hiPSC lines based on age, gender and reprogramming technology with matched controls. Ncardia has a menu of qualified induced pluripotent stem cell lines that we routinely utilize in commercial products, innovation developments and in the service of client projects. We also have established relationships with 3rd party partners, including leading hospitals and consortiums, from which we routinely source healthy and patient hiPSC lines.
All iPSC lines undergo standard quality control including sterility, mycoplasma testing, pluripotency analysis by FACS, and genome integrity by digital PCR and STR analysis. Relevant documentation and medical ethical approvals for derivation of iPSC lines are confirmed and secured by Ncardia.